United voluntarily discontinues Phase 3 trial of functional dyspepsia treatment

United announced on the 23rd that it has voluntarily decided to discontinue the Phase 3 clinical trial of the functional dyspepsia treatment (UI028).

The company stated, "We consulted with regulatory agencies such as the Health Insurance Review and Assessment Service and the Ministry of Food and Drug Safety to review economic feasibility, but determined that achieving the drug price target set by our company is difficult," adding, "We have decided to discontinue the Phase 3 clinical trial as continuing development is not beneficial to the company."